Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Gianfranco Dedivitiis"'
Autor:
Carlo Vignati, Alessandra Pietragalla, Gianfranco Dedivitiis, Maria Elisabetta Mancini, Piergiuseppe Agostoni
Publikováno v:
European Journal of Case Reports in Internal Medicine (2024)
Background: Acute mediastinitis is rarely caused by haematogenous spread of a remote infection. In this respect, since the only medical therapy is usually unsuccessful, treating acute mediastinitis with no source of infection detected is very challen
Externí odkaz:
https://doaj.org/article/72eb5257558443bc935069447809a936
Autor:
Marta Colaneri, Giovanni Scaglione, Federico Fassio, Lucia Galli, Alessia Lai, Annalisa Bergna, Arianna Gabrieli, Maciej Tarkowski, Carla Della Ventura, Valeria Colombo, Laura Cordier, Davide Bernasconi, Mario Corbellino, Gianfranco Dedivitiis, Silvia Borghetti, Debora Visigalli, Salvatore Sollima, Giacomo Casalini, Giuliano Rizzardini, Andrea Gori, Spinello Antinori, Agostino Riva, Monica Schiavini
Publikováno v:
Virology Journal, Vol 21, Iss 1, Pp 1-6 (2024)
Abstract Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear.
Externí odkaz:
https://doaj.org/article/68bbacdf9cc048d6a64fb64259aeb248
Autor:
Fabio Borgonovo, Carlo Alberto Stangalini, Carmine Tinelli, Chiara Mariani, Davide Mileto, Maria Vittoria Cossu, Laura Abbati, Lara Bilardo, Gloria Gagliardi, Miriam Cutrera, Martina Pellicciotta, Luciana Armiento, Gianfranco Dedivitiis, Amedeo F. Capetti, Giuliano Rizzardini
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Vaccination toward SARS-CoV-2 reduced mortality and ‘boosters’ are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the
Externí odkaz:
https://doaj.org/article/5934b4c6d3aa40d09f2d3daf13f8fda8
Autor:
Chiara Mariani, Fabio Borgonovo, Amedeo F Capetti, Letizia Oreni, Maria Vittoria Cossu, Martina Pellicciotta, Luciana Armiento, Simona Bocchio, Gianfranco Dedivitiis, Angelica Lupo, Massimo Galli, Giuliano Rizzardini
Publikováno v:
The Journal of Infection
Autor:
Andrea Giacomelli, Fabio Borgonovo, Angelica Lupo, Valentina Morena, Gianfranco Dedivitiis, Stefania Falvella, Letizia Oreni, Amedeo Capetti, Maria Vittoria Cossu, Matteo Passerini, Marco Piscaglia
Publikováno v:
The Journal of Infection
Journal of Infection
Journal of Infection
Autor:
Gianfranco Dedivitiis, Chiara Mariani, Paola Meraviglia, Fabio Borgonovo, Gloria Gagliardi, Maria Vittoria Cossu, Giuliano Rizzardini, Martina Pellicciotta, Davide Mileto, Angelica Lupo, Luciana Armiento, Amedeo Capetti
Publikováno v:
The Journal of Infection
Data are presented of 368/503 post-COVID-19 outpatients followed within the AntiCROWN Cohort who have a one-year control and a baseline assessment of anti-S1/S2 antibodies, detected with the The LIAISON® SARS-CoV-2 S1/S2 IgG solution by DiaSorin. Lo
Autor:
Carlo A Stangalini, Maria Vittoria Cossu, Andrea Giacomelli, Letizia Oreni, Amedeo Capetti, Davide Mileto, Angelica Lupo, Gianfranco Dedivitiis, Massimo Galli, Lara Bilardo, Fabio Borgonovo, Giuliano Rizzardini
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Autor:
Amedeo Capetti, Simona Landonio, Gianfranco Dedivitiis, Noemi Astuti, Fosca Niero, Giuliano Rizzardini, Stefania Vimercati
Publikováno v:
Journal of Antivirals & Antiretrovirals.
In poorly adherent HIV-infected subjects strategic approaches may avoid resistance to long-acting compounds. This study means to assess the safety of a strategy which was being carried out in our Division in several nonadherent subjects with general
Autor:
Fosca Niero, Amedeo Capetti, Gianfranco Dedivitiis, Giuliano Rizzardini, Mariangela Micale, Laura Carenzi, Stefania Vimercati, Simona Landonio
Publikováno v:
Medicine. 96:e5728
In view of the forthcoming long-acting antiretrovirals, measures should be taken to prevent the selection of HIV drug resistance mutations. All subjects who had been switched to boosted protease inhibitors plus maraviroc (bPIs/MVC) with baseline HIV-
Autor:
E. Angeli, Laura Valsecchi, Cecilia Gulisano, Monica Schiavini, Stefania Merli, Chiara Atzori, Elena Ricci, Giuliano Rizzardini, Riccardo Giorgi, Davide Minisci, Gianfranco Dedivitiis, Rosangela Beretta, Agostino Zambelli, Luisa Zampini, Guido Gubertini, Laura Cordier, Giovanna Orlando, Francesca Mazza, Marco Fasan, Annalisa Mainini, Paola Meraviglia, M.M. Fasolo
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 55:e12-e14